gynipral solutie injectabila 10 mcg/2 ml
nycomed austria gmbh - solutie injectabila - 10 mcg/2 ml
methylergobrevin solutie injectabila 200 mcg/ml
hemofarm ad - methylergometrinum - solutie injectabila - 200 mcg/ml
minirin spray nazal, solutie 10 mcg/doza
ferring international center sa - desmopressinum - spray nazal, solutie - 10 mcg/doza
rinofluimucil spray nazal, solutie 10 mg + 5 mg
zambon s.p.a. - acetylcysteinum + tuaminoheptanum - spray nazal, solutie - 10 mg + 5 mg
apo-desmopressin spray spray nazal, solutie 10 mcg/doza
aa pharma inc. - desmopressinum - spray nazal, solutie - 10 mcg/doza
xylo-nazal 0,1% picături nazale, soluţie
rompharm company srl, sc - xylometazolinum - picături nazale, soluţie - 0,1%
broncholytin 5,75 mg + 4,6 mg/5 ml sirop
sopharma plc - glaucinum + ephedrinum - sirop - 5,75 mg + 4,6 mg/5 ml
biresp spiromax
teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - medicamente pentru afecțiuni obstructive ale căilor respiratorii, - asthma biresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdbiresp spiromax is indicated in adults, aged 18 years and older, for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).
duoresp spiromax
teva pharma b.v. - budesonide, formoterol fumarate dihydrate - pulmonary disease, chronic obstructive; asthma - medicamente pentru afecțiuni obstructive ale căilor respiratorii, - asthma duoresp spiromax is indicated in adults and adolescents (12 years and older) for the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β₂ adrenoceptor agonist) is appropriate:in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β₂ adrenoceptor agonists. orin patients already adequately controlled on both inhaled corticosteroids and long-acting β₂ adrenoceptor agonists. copdduoresp spiromax is indicated in adults, aged 18 years and older for the symptomatic treatment of patients with copd with forced expiratory volume in 1 second (fev₁).
xylo-nasal 1 mg/ml
rompharm company s.r.l. - romania - xylometazolinum - pic. nazale, sol. - 1mg/ml - decongestionante si alte medicamente nazale de uz topic simpatomimetice